[go: up one dir, main page]

EP1311236A1 - UTILISATION DE $g(b)-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES - Google Patents

UTILISATION DE $g(b)-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES

Info

Publication number
EP1311236A1
EP1311236A1 EP01969596A EP01969596A EP1311236A1 EP 1311236 A1 EP1311236 A1 EP 1311236A1 EP 01969596 A EP01969596 A EP 01969596A EP 01969596 A EP01969596 A EP 01969596A EP 1311236 A1 EP1311236 A1 EP 1311236A1
Authority
EP
European Patent Office
Prior art keywords
compounds
formulas
formulation according
cosmetic
human skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01969596A
Other languages
German (de)
English (en)
Inventor
Thomas Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitop Gesellschaft fur Biotechnische Optimierung mbH
Original Assignee
Bitop Gesellschaft fur Biotechnische Optimierung mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitop Gesellschaft fur Biotechnische Optimierung mbH filed Critical Bitop Gesellschaft fur Biotechnische Optimierung mbH
Publication of EP1311236A1 publication Critical patent/EP1311236A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • the invention relates to the use of one or more chemical compounds selected from the compounds of the formulas la (Firoin) and Ib (Firoin-A) in cosmetic and dermatological formulations.
  • the invention relates e.g. the production of a cosmetic or dermatological formulation for protecting and stabilizing human skin cells and their organic components, such as Proteins, enzymes, membranes, nucleic acids or antioxidants.
  • the invention includes the use of physiologically compatible salts of the compounds Ia and Ib, the stereoisomeric forms of the compounds of the formulas Ia and Ib and derivatives of these compounds (for example esters) for use in cosmetic and dermatological formulations.
  • the cell's own repair systems DNA repair after UV damage, induction and stabilization of the chaperon proteins for the refolding of (partially) denatured proteins and enzymes
  • Firoin ß-mannosylglycerate
  • Firoin-A ß-mannosylglyceramide
  • Firoine Due to their low molecular weight, Firoine reach the inside of the target cells through several layers of skin and can bring other active ingredients from the cosmetic formulation (e.g. proteins, enzymes, vitamins, antioxidants) to the actual destination as co-solvents or penetration enhancers.
  • cosmetic formulation e.g. proteins, enzymes, vitamins, antioxidants
  • Firoine Due to its chemical structure, Firoine are compatible with the majority of the usual cosmetic basic formulations and further modifications to the suitable form of application are possible by appropriate modifications of the functional side chains. Firoine is moisturizing due to the large number of hydroxyl groups and gives a pleasant feeling on the skin. Compatible solutes act as natural solvents in extremophilic microorganisms and stabilize enzymes, proteins and other cell components by generating a more native, globular state that not only protects the proteins from proteolysis, but also keeps them in a more compact and active state. Firoins can be used as co-solvents or penetration enhancers for cosmetic active ingredients, particularly with regard to the possible derivatization of individual functional groups in a wide field.
  • the invention thus relates to the use of Firoin and Firoin-A as additives and active ingredients with a completely new mode of action in cosmetic and dermatological preparations and products.
  • UV filters Today's skin and sunscreen products include two classes of UV filters. Physically effective UV filters consist of inorganic compounds (e.g. titanium dioxide) that reflect the light that hits the skin. Chemically acting organic molecules absorb UV light of the wavelengths that are responsible for the formation of erythema (sunburn) (primarily 295 to 323 nm with a maximum at 308 nm).
  • inorganic compounds e.g. titanium dioxide
  • chemically acting organic molecules absorb UV light of the wavelengths that are responsible for the formation of erythema (sunburn) (primarily 295 to 323 nm with a maximum at 308 nm).
  • radical scavengers and antioxidants are used as additives in cosmetic formulations to protect against oxidative stress, which is caused by environmental influences (UV radiation, smoke, chemical substances) but also by the cell's own activities.
  • the range of active ingredients covers both water-soluble radical scavengers (e.g. ascorbic acid), which act in the interior of the liquid, and fat-soluble antioxidants (e.g. retionol palmitate or ⁇ -tocopherol), which are effective in membrane structures. It is rarely taken into account that with topical applications of these active ingredients, at most 3% reach a deeper skin layer and the rest remains ineffective on the skin surface.
  • Hyperthermophiles are very unusual microorganisms, because they grow optimally at temperatures (60-110 ° C) that at mesophilic ("normal") Organisms would cause massive damage to cellular structures.
  • a great deal of research has therefore been carried out in recent years to identify the biochemical components that lead to the remarkable thermal, chemical and physical stabilization of the cell structures.
  • the focus of the research work was on the isolation of thermostable enzymes, since numerous enzymatically catalyzed industrial processes take place under extreme environmental conditions and suitable biocatalysts are sought.
  • thermophilic microorganisms Although many enzymes from hyperthermophilic microorganisms are stable even at high temperatures, this does not generally apply to the cellular structures of thermo- and hyperthermophilic organisms. Low molecular weight organic substances (compatible solutes, "hypersolutes”) in the intracellular milieu make a significant contribution to the high temperature stability of cell structures.
  • Various novel hypersolutes have been identified in hyperthermophilic microorganisms in recent years. In some cases, the contribution of these compounds to Protection of cellular structures - especially enzymes - against heat and drought has already been impressively demonstrated, bitop has developed technologies for the production of compatible solutes from thermophilic microorganisms.
  • the human skin is an organ that protects the body from external influences with various types of specialized cell types - the keratinocytes, melanocytes, Langerhans cells, Merkel cells and embedded sensory cells.
  • External physical influences include thermal and mechanical influences as well as the effects of radiation, for example UV, VIS and IR radiation.
  • External chemical influences are to be understood in particular as the effects of toxins, allergens and substances which bind to the deoxyribonucleic acid.
  • the outer biological Influences include the effects of foreign organisms and their metabolic products.
  • Sunburn Ervthema solare
  • UV-A radiation has a comparatively minor influence on its formation. Sunburn can range from a mild killing to a severe burn with blistering. Since these consequences occur at the earliest 4-6 h after radiation, it is too late for countermeasures. Multiple sunburns - especially in childhood - significantly increase the risk of skin cancer. The causes of this are damage, in particular the nucleic acids of human skin cells and faulty repair of the damaged deoxyribonucleic acid in the cell nucleus, and probably the immunosuppressive effect of UV radiation, i.e.
  • Excessive UV-A and UV-B exposure contributes to skin aging or light aging, e.g. in the form of structural changes in the connective tissue (actinic elastosis). Excessive UV-B exposure is the main cause of chronic skin changes.
  • Each tissue has an antioxidative potential (AOP) made up of enzymatic and non-enzymatic antioxidants, which keep the content of prooxidants below a limit value in unstressed cells, which is harmless to the healthy cell. If these natural antioxidants are inactivated or denatured, the skin's resistance and regeneration ability is significantly reduced.
  • AOP antioxidative potential
  • Firoin and Firoin-A Extremophilic microorganisms (thermophiles and hyperthermophiles) protect themselves from thermal stress through the formation of Firoin and Firoin-A. In the presence of these substances, these microbial organisms are therefore able to exist under the prevailing extreme conditions, since Firoin and Firoin-A stabilize the metabolism and the essential organic components and protect them from damage. Surprisingly, it has now been found in particular that Firoin and Firoin-A also show the stabilizing effects on human skin and thus represent ideal active ingredients and additives for cosmetic and dermatological preparations. Firoin and Firoin-A thus represent a universally applicable and completely new protective principle in cosmetics and dermatology.
  • the above-mentioned problem is selected by using one or more compounds from the compounds of the formulas la (Firoin) and Ib ( Firoin-A) dissolved in cosmetic and dermatological formulations.
  • the invention relates to the use of one or more compounds selected from the compounds of the formulas la (Firoin) and Ib (Firoin-A),
  • Possible salts of the compound la are the alkali and alkaline earth metal salts, in particular the Na and the K salt.
  • the derivatives of the compound la are their esters with physiologically tolerable alcohols, in particular the C 1 -C 4 alcohols.
  • the invention relates in particular to the use of one or more compounds selected from the compounds of the formulas Ia and Ib, the physiologically tolerable salts of the compounds of the formulas Ia and Ib and the stereoisomeric forms of the compounds of the formulas Ia and Ib for the preparation of a cosmetic or dermatological formulation to protect and stabilize human skin cells and their organic components such as Proteins, enzymes, membranes, nucleic acids, antioxidants etc. from physical, chemical and biological influences such as e.g. from radiation (UV, IR, VIS radiation), from denaturing substances, from temperature or from cold.
  • the present invention describes this principle of protection for the first time.
  • the possible uses are very diverse and can only be described by way of example within the scope of the invention.
  • the invention is not intended to be limited by giving examples.
  • Firoine carry the structural motifs of classic stabilizers (OH groups of mannose, glycerin, amino function) and thus ideally combine two important stabilization mechanisms: OH group stabilization (e.g. trehalose, sucrose, hydroxyectoin) and preferential exclusion (e.g. ectoin): • Binding of hydrophilic protein domains via OH groups (simulation of water), prevention of hydrogen bonding within the protein structure and between proteins during drying and rehydration.
  • OH group stabilization e.g. trehalose, sucrose, hydroxyectoin
  • preferential exclusion e.g. ectoin
  • Preferentiai exclusion in the stabilization over denaturation e.g. through thermal stress Preferentiai exclusion in the stabilization over denaturation e.g. through thermal stress.
  • Firoin is characterized by the following features:
  • Firoin as a substitute for water in the cell should not be forgotten.
  • Firoin like the other Compatible Solutes, is the cell's natural solvent. In order to be able to develop their effect in the cell at all, biogenic substances have to be solubilized.
  • Liposomes gain as skin-permeable vehicles e.g. for active substances not only in cosmetics more and more important. Liposomes are artificial lipid double layers - artificial membranes - the stability of which is limited, however, so that there is a need to stabilize liposome preparations e.g. against temperature stress and osmotic stress in order to achieve better storage and transport properties. This is the only way to ensure optimal use of active ingredients via liposomes.
  • Membranes represent the natural barriers of cells and cell organelles to the medium surrounding them. Only membranes ensure that there is a constant internal environment in the individual cells or cell components. Biological membranes are multi-component systems. The exact composition of individual membranes is subject to varying fluctuations depending on their origin. However, elementary components of membranes are lipids and proteins. Lipids can be divided into the so-called “simple" lipids such as fats and waxes and "complex" lipids. In addition to phospholipids, which are derived from sn-glycerol-3-phosphoric acid, there are phosphate-free lipids such as glycolipids in the cell. Glycolipids contain covalently bound carbohydrate residues. The carbohydrates are glycosidically linked to the primary hydroxyl group of the alcohol component. In addition to the glycoproteins, the glycolipids play an essential role in the interaction of the cells with one another and with biologically active molecules (eg as a component of receptors).
  • glycolipids are present in the membranes in the form of glyceroglycolipids. These compounds are characterized by the glycosidic linkage of a glycerol residue with a carbohydrate residue.
  • the following figure shows an example of a group of these compounds in which a mannose residue represents the carbohydrate portion of the lipid.
  • the organic residues R1 and R2 generally represent Fatty acids, carbohydrates or sulfonic acid groups which are esterified with the alcoholic groups of the glycerol residue.
  • the Compatible Solut Firoin is the condensation product of mannose and glyceric acid.
  • the comparison of the structure of this compound with that of the above. Glycolipids shows a clear structural analogy of both components.
  • biogenic agents e.g. proteins
  • Firoin is important as a skin moisture regulator. Due to the presence of numerous hydroxyl groups in the molecule and high stability, Firoin has a particularly pronounced suitability as a heat-resistant moisture regulator with a depot effect. This is particularly important for regulating the skin's moisture balance.
  • Firoin like the other Compatible Solutes, is the cell's natural solvent.
  • biogenic substances have to be solubilized.
  • Dehydration processes irreversibly damage skin components. Cells, membranes and proteins are destroyed.
  • the skin's resistance and its ability to regenerate decrease.
  • skin aging processes run faster. In principle, the same process as drying out the skin takes place during freeze drying, the stress conditions are only much greater. It can therefore at least plausibly be deduced from the protective potential of Firoin during freeze drying that Firoin can be more than just a moisturizer in drying processes, but also an active protective agent.
  • the commercial application of the invention is in the entire field of cosmetic and dermatological products and as research reagents in the field of cosmetic and dermatological development.
  • the cosmetic and dermatological formulations are prepared by one or more compounds of the formulas la and Ib (Firoin and / or Firoin-A), the physiologically tolerable salts of the compounds of the formulas la and Ib, the stereoisomeric forms of the compounds of the formulas la and Ib or derivatives, if appropriate with auxiliaries and / or carriers, are brought into a suitable formulation.
  • the auxiliaries and carriers come from the group of carriers, preservatives and other customary auxiliaries.
  • the compounds of the formulas Ia and Ib (Firoin and / or Firoin-A) contained in cosmetic and dermatological formulations, the physiologically tolerable salts of the compounds of the formulas Ia and Ib and the stereoisomeric forms of the compounds of the formulas Ia and Ib are used externally.
  • an application form e.g. called: solutions, suspensions, emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleaning preparations, oils and sprays.
  • any customary excipients, auxiliaries and, if appropriate, further active ingredients can be added to the formulations.
  • Preferred additives come from the group of preservatives, antioxidants, stabilizers, solubilizers, vitamins, colorants and odor improvers.
  • ointments, pastes, creams and gels can contain the usual carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
  • carriers e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
  • powders and sprays can contain the customary blowing agents, for example chlorofluorocarbons, propane / butane or dimethyl ether, in addition to the customary carriers.
  • solutions and emulsions can additionally contain the customary carriers, such as solvents, solubilizers and emulsifiers or oils.
  • suspensions can be selected from the compounds of the formulas Ia and Ib and additional carriers, such as Contain water or ethanol.
  • the proportion of the compounds of the formulas la (Firoin) and Ib (Firoin-A), the physiologically tolerable salts of the compounds la and IB, and the stereoisomeric forms of the compounds of the formulas la and Ib in cosmetic and dermatological formulations is preferably from 0.0001 to 50% by weight, particularly preferably from 0.001 to 10% by weight, based on the entire cosmetic formulation.
  • Firoinen support e.g. the cell's own antioxidative potential through proven stabilization against thermal protein denaturation and inactivation. Damage caused by radicals is thus counteracted. Due to the proven DNA protection of compatible solutes and their protein-stabilizing effect, the use of firoinen according to the invention represents a new type of active sun protection (e.g. UV and IR radiation) in cosmetics and dermatology.
  • active sun protection e.g. UV and IR radiation
  • a lotion (O / W) according to the invention containing Firoin is produced from the following components:
  • a cream (O / W) according to the invention containing Firoin is produced from the following components:
  • a liposome-containing gel containing Firoin is produced from the following components:
  • An inventive gel (O / W) containing Firoin is produced from the following components:
  • a sunscreen emulsion containing Firoin is produced from the following components:
  • An emulsifier-free sun lotion SPF 30 (W / O) containing Firoin is produced from the following components:
  • An inventive hair tonic containing Firoin is produced from the following components:
  • a spray formulation according to the invention containing Firoin is produced from the following components:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'incorporation dans des formulations cosmétiques ou dermatologiques destinées à protéger la peau des influences écologiques et augmenter le pouvoir de régénération de la peau, de la substance de faible poids moléculaire β-mannosylglycérate (firoïne) (soluté compatible) à base de micro-organismes et/ou de dérivés de ce composé, par ex. un acide, un sel ou un ester, notamment le β-mannosylglycéramide (firoïne-A). Selon l'invention, les firoïnes (β-mannosylglycérate et β-mannosylglycéramide) participent à la protection cellulaire active des capteurs de radicaux spécifiques des cellules, à celle des protéines, des antioxydants, de l'ADN, des membranes cellulaires et d'autres compartiments cellulaires, du fait qu'elles protègent des influences écologiques nocives, par ex. des rayons U.V., des rayons infrarouges et des agressions du milieu (d'ordre thermique, chimique et physique). Pour d'autres principes actifs ajoutés à la formulation cosmétique, les firoïnes peuvent servir de co-solvants et de renforçateurs de pénétration, afin non seulement de les stabiliser dans la formulation cosmétique, mais également de les transporter de manière active dans des couches plus profondes de la peau.
EP01969596A 2000-08-18 2001-08-16 UTILISATION DE $g(b)-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES Withdrawn EP1311236A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10040933 2000-08-18
DE10040933A DE10040933A1 (de) 2000-08-18 2000-08-18 Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen
PCT/EP2001/009445 WO2002015867A1 (fr) 2000-08-18 2001-08-16 UTILISATION DE β-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES

Publications (1)

Publication Number Publication Date
EP1311236A1 true EP1311236A1 (fr) 2003-05-21

Family

ID=7653225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01969596A Withdrawn EP1311236A1 (fr) 2000-08-18 2001-08-16 UTILISATION DE $g(b)-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES

Country Status (6)

Country Link
US (1) US20050100534A1 (fr)
EP (1) EP1311236A1 (fr)
JP (1) JP2004506675A (fr)
AU (1) AU2001289806A1 (fr)
DE (1) DE10040933A1 (fr)
WO (1) WO2002015867A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10330243A1 (de) * 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
DE102004049062A1 (de) * 2004-03-30 2005-10-13 bitop Aktiengesellschaft für biotechnische Optimierung Topische Zubereitung zur Anwendung auf der Haut enthaltend natürliches Öl der Nachtkerze (Oenothera biennis) (=Oleum Oenothera) und Osmolyte aus extremophilen Mikroorganismen
EP1891854A1 (fr) * 2006-08-21 2008-02-27 Shell Internationale Researchmaatschappij B.V. Procédé et composition pour irriguer des plantes
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
DE102007052380A1 (de) † 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
JP5754796B2 (ja) * 2010-07-26 2015-07-29 国立研究開発法人産業技術総合研究所 抗酸化剤及びその利用
CN106093430A (zh) * 2016-06-06 2016-11-09 上海阿趣生物科技有限公司 可用于检测糖尿病的标志物及其用途
FR3061013B1 (fr) * 2016-12-22 2020-04-17 Greenpharma Composition contenant le digeneaside, son procede d'obtention et son utilisation cosmetique, veterinaire ou nutraceutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101887A (pt) * 1996-06-28 1998-01-30 Inst De Biolog Ex E Tecnologic Utilizacao de 2-0- -manosilglicerato para termoestabilizacao, osmoproteccao e proteccao contra a desidratacao de enzimas, outros componenetes celulares e celulas
EP1125583A1 (fr) * 2000-02-14 2001-08-22 Bitop Gesellschaft für biotechnische Optimierung MbH Utilisation de solutés compatibles en tant qu inhibiteur de la dégradation enzymatique de biopolymères macromoléculaires
EP1272201B1 (fr) * 2000-04-12 2004-11-24 Bitop Aktiengesellschaft Für Biotechnische Optimierung Utilisation de solutes compatibles en tant que substances aux proprietes de piegeage de radicaux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0215867A1 *

Also Published As

Publication number Publication date
US20050100534A1 (en) 2005-05-12
DE10040933A1 (de) 2002-03-07
JP2004506675A (ja) 2004-03-04
AU2001289806A1 (en) 2002-03-04
WO2002015867A1 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
EP1311238B1 (fr) Utilisation de di-sucres de phosphate d'alcool pour proteger les cellules de la peau humaine contre les radiations uv et/ou ir
DE69523169T2 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
DE69426064T2 (de) Kosmetische Zusammensetzung enthaltend einen pflanzlichen extrazellularen Matrixextrakt
DE4228455A1 (de) Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
DE102010017151A1 (de) Verwendung eines polyphenolreichen Pflanzenextraktes als Antioxidans in Kombination mit einem Feuchtigkeits- oder Feuchthaltemittel
EP1673068B1 (fr) Composition cosmetique favorisant le transport d'oxygene dans la peau
DE10136077A1 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
WO2000007558A1 (fr) Utilisation d'ectoine ou de derives d'ectoine dans des formulations cosmetiques
EP1311236A1 (fr) UTILISATION DE $g(b)-MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES
DE102004049062A1 (de) Topische Zubereitung zur Anwendung auf der Haut enthaltend natürliches Öl der Nachtkerze (Oenothera biennis) (=Oleum Oenothera) und Osmolyte aus extremophilen Mikroorganismen
DE69829838T2 (de) Verfahren zur stabilisierung von linksdrehender ascorbinsäure (laa) und stabile zusammensetzungen von laa
DE69712099T2 (de) Verwendung eines aucoumea-harz extraktes als kosmetikum und pharmazeutikum, insbesondere als dermatologikum
WO2003011241A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
EP1311237A2 (fr) Utilisation de 2,4-diphosphoglycerate cyclique (cdgp) et/ou de derives dans des formulations cosmetiques et dermatologiques
KR102278167B1 (ko) 지질산화 방지, 자외선에 의한 손상 피부 개선 및 피부 진정 효과가 우수한 화장료 조성물
DE10055706A1 (de) Verwendung von Di-Glycerinphosphat (DGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen
DE10040932A1 (de) Verwendung von Di-myo-inositolphosphat (DIP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen
KR101583478B1 (ko) 항자극용 화장료 조성물
WO2008006485A1 (fr) Préparations cosmétiques ou dermatologiques contenant de l'acide folique et un ou plusieurs polyols
KR20220060036A (ko) 케라틴을 함유하는 항염증 조성물
KR20230086211A (ko) 보검 선인장 줄기 추출물 및 테킬라 용설란 잎 추출물을 포함하는 화장료 조성물
DE102010004937A1 (de) Verwendung von Salicylsäureestern zur Geruchsmaskierung von Abbauprodukten des Harnstroffs
DE102011085535A1 (de) Kosmetische oder dermatologische Wasser–in–Öl-Emulsionen mit einem Gehalt anHarnstoff und Polyglyceryl-4 Diisostearat/Polyhydroxystearat/Sebacat.
WO2008006484A1 (fr) Préparations cosmétiques ou dermatologiques contenant de l'acide folique, des silicones volatiles et des silicones non volatiles
EP1301171A1 (fr) Utilisation de fractions proteiques solubles extraites

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20030312

17Q First examination report despatched

Effective date: 20040402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050616